Predict your next investment

Rock Health company logo
Venture Capital
FINANCE | Investment Firms & Funds
rockhealth.com

See what CB Insights has to offer

Investments

111

Portfolio Exits

22

Funds

2

Partners & Customers

7

About Rock Health

Rock Health funds and supports startups building healthcare technologies. Rock Health provides entrepreneurs with funding, strategic and operational support, co-working space, and access to a network of partners, academic medical centers, and clinicians. The company was founded in 2010 and is based in San Francisco, California.

Rock Health Headquarters Location

455 Mission Bay Blvd S Suite 124

San Francisco, California, 94158,

United States

617-459-2712

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Rock Health

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Rock Health in 3 Expert Collections, including Wearable Computing.

W

Wearable Computing

16 items

Wearable computing is broadly defined to include companies developing electronics devices worn or placed on the body and equipped with technology that can range from wearable medical devices to AR/VR headsets to GPS pet collars, among other examples. We include any company with a

C

Conference Exhibitors

5,501 items

HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare

I

Insurtech

35 items

Rock Health Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Rock Health Rank

Latest Rock Health News

At 6.4% CAGR, Global Pleural Effusions Treatment Market Size & Share to Surpass US$ 6.8 Billion By 2028 | Pleural Effusions Treatment Industry Trends, Share, Growth, Value, Analysis & Forecast Report By ZMR

Jul 26, 2022

News provided by Share this article Share this article NEW YORK, July 26, 2022 /PRNewswire/ -- As per Zion Market Research study, The global pleural effusions treatment market size was worth around USD 4.4 billion in 2021 and is predicted to grow to around USD 6.8 billion by 2028 with a compound annual growth rate (CAGR) of roughly 6.4% between 2022 and 2028. Pleural Effusions Treatment Market: Overview Pleural effusion is also known as water on the lungs and occurs when excess fluid builds up between the pleura layers outside the lungs. Pleura are thin membranes that line the inside of the chest cavity and lungs in order to facilitate breathing and enhance lubrication. In normal situations, a small amount of fluid is present in these membranes but when the amount exceeds the normal value, is when pleural effusion takes place and has to be treated medically. Pleural effusion seriousness depends on factors like the cause of the effusion, if breathing is obstructed, and if the condition can be effectively treated. In case, the effusion is caused due to heart failure, pneumonia, or a virus, the cause can be treated or controlled. Pleural effusion is a tricky medical condition owing to the fact that patients do not show any visible symptoms, and the condition is detected during a chest x-ray for any other purpose. However, the most generic symptoms that may be unrelated but may arise depending on the cause of effusion are dry or nonproductive cough, chest pain, dyspnea, and orthopnea. As per National Cancer Center, pleural effusions are extremely common and affect over 1 million of the population in the USA, every year. Get a Free Sample Report with All Related Graphs & Charts (with COVID 19 Impact Analysis): https://www.zionmarketresearch.com/sample/pleural-effusions-treatment-market Our Free Sample Report Includes: 2022 Updated Report Introduction, Overview, and In-depth industry analysis COVID-19 Pandemic Outbreak Impact Analysis Included 264 + Pages Research Report (Inclusion of Updated Research) Provide Chapter-wise guidance on Request 2022 Updated Regional Analysis with Graphical Representation of Size, Share & Trends Includes an Updated List of tables & figures Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis Zion Market Research methodology Key Industry Insights & Findings of the Pleural Effusions Treatment Market Reports: As per the analysis shared by our research analyst, the Pleural Effusions Treatment Market is expected to grow annually at a CAGR of around 6.4 % (2022-2028). Through the primary research, it was established that the Pleural Effusions Treatment Market was valued at approximately USD 4.4 Billion in 2021 and is projected to reach roughly USD 6.8 Billion by 2028. The global pleural effusions treatment market cap is expected to be dominated by North America in the coming years owing to the large-scale investment in the pharmaceutical sector along with the presence of excellent medical reimbursement policies and advanced healthcare infrastructure. As per Deloitte's analysis of the Rock Health Database, healthcare innovators in the USA received venture funding of USD 14 Billion in 2020, which was twice the funding in 2019. Asia-Pacific may also register high CAGR because of the increasing prevalence of respiratory disorders along with the rise in TB and lung cancer. China is being considered to be in the middle of a lung cancer epidemic or at least rising exponentially which may aid regional growth during the forecast period. The total number of pleural effusion cases registered per year ranges from 4 to 5 million which is an indication of how common the disease is and if left untreated may result in death. Lung cancer is also a common disease globally which has been following a rising trend in the last few years. Rise in heart and lungs conditions to aid global market growth The global pleural effusions treatment market growth may be propelled by the rising number of medical cases pertaining to congestive heart failure, pneumonia, lung cancer, and tuberculosis. In Germany, the total number of pleural effusion cases registered per year ranges from 4 to 5 million which is an indication of how common the disease is and if left untreated may result in death. Lung cancer is also a common disease globally which has been following a rising trend in the last few years. As per reports submitted by American Lung Association, in 2018, over 13% of the diagnosed cancer cases were related to lung cancer. In 2022, 2.3 million new cases of lung cancer were registered whereas the country witnessed over 1.3 million deaths related to lung cancer. Some of the reasons for the high prevalence of lung cancer include the rise in exposure to second-hand smoke, along with radon gas, asbestos, or other carcinogens. The increase is also propelled by the growing smoking industry. The global market size may also benefit from the increase in the proper diagnosis of the disease. Since pleural effusions are extremely common, almost all doctors and physicians recommend the test even during check-ups for other problems. It is very common that a patient suffering from systemic lupus erythematosus may also contact pleural effusions. Over 25% to 45% of systemic lupus erythematosus patients have been affected by pleural effusions. The growing trend of awareness related to the disease may help global market growth. Pleural Effusions Treatment Market: Restraints Discomfort associated with treatments related to pleural effusions may restrict the global market growth Pleural effusion invasive treatments may lead to minor discomfort or pain which do not last for a long time. The severity of the after-effects may depend on the underlying cause of pleural effusions, the intensity of the cause, and other treatments associated with the cause. For example, if the thoracentesis fluid drains too quickly it may result in pulmonary edema and may lead to intense complications. The global market growth trend may also witness some resistance due to the unsatisfactory success rate of pleural effusion treatments since the disease goes undetected many times due to the absence of concrete symptoms. The treatments for the disease undergo multiple variations depending on the underlying cause and its intensity. For example, in case of congestive heart failure with no signs of chest pain or fever should be treated with diuretics before thoracentesis. Directly Purchase a Copy of the Report @ https://www.zionmarketresearch.com/buynow/su/pleural-effusions-treatment-market Pleural Effusions Treatment Market: Opportunities Advancements in the understanding of the disease provide growth opportunities for global market expansion Since pleural effusions are extremely common and can occur as a result of different main causes, the global market is witnessing a rising research trend on understanding the root causes and efficient treatment for the medical condition. European Respiratory Journal published that malignant pleural effusions are common in patients suffering from neoplastic diseases. As per their report, amongst the total number of patients who died with malignancies, 15% were detected with malignant effusions. The growing interest of the healthcare sector in learning about the virus is expected to expand the global market cap in the coming years. Pleural Effusions Treatment Market: Challenges Lack of skilled professionals in emerging economies to challenge global market growth The emerging economies are severely underfunded as compared to the need for developed healthcare infrastructure. There is a lack of sufficient skilled medical staff to cater to the growing healthcare demands of the population. The absence of enough healthcare facilities, attractive medical reimbursement plans, etc. is restricting the emerging economies from attaining full potential in the healthcare sector. As of 2040, the healthcare expenditure globally will rise to up to USD 18 trillion which may restrain the growth in poor economies even further. Global Pleural Effusions Treatment Market: Segmentation The global pleural effusions treatment market is segmented based on treatment, type, end-user, and region. Based on treatment, the global market segments are catheter, thoracentesis, pleuroperitoneal shunt, pleurodesis, and others. Thoracentesis treatment is used in case of large effusions whereas pleurodesis can prevent pleural effusions from coming back. In the USA, thoracentesis is performed more than 1.7 million times a year. By type, exudative and transudative are the two global market segments where transudative type leads the segment. It occurs when the systemic factor causing absorption or formation of pleural fluid is altered. Almost 6% of the patients suffering from liver cirrhosis get diagnosed with pleural effusion that is associated with ascites, which is the leading source of transudative effusion. By end-user, the global market is segmented into ambulatory clinics, clinics, hospitals, and others. The global market is expected to be dominated by the hospital segment during the forecast period. List of Key Players in Pleural Effusions Treatment Market: TruCorp Cardinal Health Recent Developments In January 2020, Argon Medical launched single and triple loop retrieval kits for its USA market with the aim to enhance the lives of patients. The products have managed to secure the approval from US Food and Drug Administration, and are effective in the removal of retrievable IVC filters with the help of a jugular approach. The single and triple loop retrieval kits are the only 2 kits to have received FDA approval in terms of any retrievable IVC filter from a jugular approach. In May 2021, FDA approved first-of-its-kind targeted therapy for lung cancer mutation which was up until now considered drug resistant. The therapy is called Lumakras (sotorasib) and will be used for adult patients who have non-small cell lung cancer where the tumor has genetic mutation called KRAS G12C and patients should have undergone at least one systemic therapy. Regional Dominance: North America to dominate the global market during the forecast period The global pleural effusions treatment market cap is expected to be dominated by North America in the coming years owing to the large-scale investment in the pharmaceutical sector along with the presence of excellent medical reimbursement policies and advanced healthcare infrastructure. As per Deloitte's analysis of the Rock Health Database, healthcare innovators in the USA received venture funding of USD 14 Billion in 2020, which was twice the funding in 2019. This is being seen as a new era for multiple opportunities in the healthcare sector thus propelling regional growth. Asia-Pacific may also register high CAGR because of the increasing prevalence of respiratory disorders along with the rise in TB and lung cancer. China is being considered to be in the middle of a lung cancer epidemic or at least rising exponentially which may aid regional growth during the forecast period. Global Pleural Effusions Treatment Market is segmented as follows: Pleural Effusions Treatment Market: By Treatment Outlook (2022-2028) Catheter Press Release For Pleural Effusions Treatment Market: https://www.zionmarketresearch.com/news/global-pleural-effusions-treatment-market Browse Other Related Research Reports from Zion Market Research Quadriplegia Treatment Market - Global Industry Analysis : The global quadriplegia treatment market is projected to grow with a compound annual growth rate (CAGR) of approximately 4.2 percent during the forecast period. Hospital-Acquired Infection Control Market - Global Industry Analysis : The global hospital-acquired infection control market was valued at USD 28.99 billion in 2021. The global market is projected to grow to about USD 34.03 billion at a CAGR of 9.89% by 2028. Chronic Respiratory Diseases Treatment Market - Global Industry Analysis : The global chronic respiratory diseases treatment market size was worth around USD 143 billion in 2021 and is predicted to grow to around USD 300 billion by 2028 with a compound annual growth rate (CAGR) of roughly 17.5% between 2022 and 2028. Browse through Zion Market Research's coverage of the Global Healthcare Industry About Us Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, and company reports to country report. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us. Contact Us:

Rock Health Investments

111 Investments

Rock Health has made 111 investments. Their latest investment was in Ribbon Health as part of their Series B on November 11, 2021.

CBI Logo

Rock Health Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/16/2021

Series B

Ribbon Health

$43.5M

Yes

16

7/14/2021

Seed VC

JOON

$2.3M

Yes

4

6/17/2021

Series A

Zus Health

$34M

Yes

17

10/20/2020

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

8/19/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/16/2021

7/14/2021

6/17/2021

10/20/2020

8/19/2020

Round

Series B

Seed VC

Series A

Seed VC

Series A

Company

Ribbon Health

JOON

Zus Health

Subscribe to see more

Subscribe to see more

Amount

$43.5M

$2.3M

$34M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

16

4

17

10

10

Rock Health Portfolio Exits

22 Portfolio Exits

Rock Health has 22 portfolio exits. Their latest portfolio exit was DrChrono on November 02, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/2/2021

Acquired

$99M

8

10/21/2021

Acquired

$99M

4

10/19/2021

Acquired

$99M

1

3/16/2021

Merger

Subscribe to see more

$99M

Subscribe to see more

10

10/6/2020

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/2/2021

10/21/2021

10/19/2021

3/16/2021

10/6/2020

Exit

Acquired

Acquired

Acquired

Merger

Reverse Merger

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

8

4

1

10

10

Rock Health Fund History

2 Fund Histories

Rock Health has 2 funds, including Rock Health Seed Fund II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/6/2015

Rock Health Seed Fund II

Early-Stage Venture Capital

Closed

$5.7M

2

Rock Health Seed Fund III

Subscribe to see more

Subscribe to see more

10

Closing Date

4/6/2015

Fund

Rock Health Seed Fund II

Rock Health Seed Fund III

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Status

Closed

Subscribe to see more

Amount

$5.7M

Sources

2

10

Rock Health Partners & Customers

7 Partners and customers

Rock Health has 7 strategic partners and customers. Rock Health recently partnered with Blue Shield of California on December 12, 2018.

Date

Type

Business Partner

Country

News Snippet

Sources

12/17/2018

Partner

United States

A Rock Health partnership snapshot: Blue Shield of California. How an eighty-year-old health plan is building the healthcare model of the future by working with Rock Health

Through its partnership with Rock Health , Blue Shield of California has showcased thought leadership , collaborated on research , and gained unparalleled insight into the frontlines of healthcare innovation .

1

6/18/2018

Partner

United States

Subscribe to see more

Subscribe to see more

10

11/10/2015

Partner

United States

Subscribe to see more

Subscribe to see more

10

9/30/2015

Partner

United States

Subscribe to see more

Subscribe to see more

10

6/5/2013

Vendor

United States

Subscribe to see more

Subscribe to see more

10

Date

12/17/2018

6/18/2018

11/10/2015

9/30/2015

6/5/2013

Type

Partner

Partner

Partner

Partner

Vendor

Business Partner

Country

United States

United States

United States

United States

United States

News Snippet

A Rock Health partnership snapshot: Blue Shield of California. How an eighty-year-old health plan is building the healthcare model of the future by working with Rock Health

Through its partnership with Rock Health , Blue Shield of California has showcased thought leadership , collaborated on research , and gained unparalleled insight into the frontlines of healthcare innovation .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Rock Health Team

5 Team Members

Rock Health has 5 team members, including current Chief Executive Officer, Managing Director, Bill Evans.

Name

Work History

Title

Status

Nate Gross

Founder

Current

Halle Tecco

Founder

Current

Bill Evans

Chief Executive Officer, Managing Director

Current

Tom Cassels

President

Current

Megan Zweig

Chief Operating Officer

Current

Name

Nate Gross

Halle Tecco

Bill Evans

Tom Cassels

Megan Zweig

Work History

Title

Founder

Founder

Chief Executive Officer, Managing Director

President

Chief Operating Officer

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.